VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q56850411 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235921.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q56850411‏
024 ‎‡a 0000-0002-0601-613X‏ ‎‡2 orcid‏
024 ‎‡a 7102896260‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q56850411‏
100 0 ‎‡a Daniel F Alonso‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Daniel F Alonso‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.‏
670 ‎‡a Author's A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies‏
670 ‎‡a Author's A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.‏
670 ‎‡a Author's A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.‏
670 ‎‡a Author's Addition of vasopressin synthetic analogue [V‏
670 ‎‡a Author's Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.‏
670 ‎‡a Author's Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.‏
670 ‎‡a Author's Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients‏
670 ‎‡a Author's Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.‏
670 ‎‡a Author's Antimetastatic effect of desmopressin in a mouse mammary tumor model‏
670 ‎‡a Author's Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).‏
670 ‎‡a Author's Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.‏
670 ‎‡a Author's CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo‏
670 ‎‡a Author's CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo‏
670 ‎‡a Author's CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models‏
670 ‎‡a Author's Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured Liver‏
670 ‎‡a Author's Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.‏
670 ‎‡a Author's Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model‏
670 ‎‡a Author's Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer: Potential use of Perioperative Desmopressin to Reduce Allogenic Blood Transfusion Rates‏
670 ‎‡a Author's Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.‏
670 ‎‡a Author's Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation.‏
670 ‎‡a Author's Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry‏
670 ‎‡a Author's Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA.‏
670 ‎‡a Author's Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.‏
670 ‎‡a Author's Effect of atorvastatin in a case of feline multicentric lymphoma - Case report‏
670 ‎‡a Author's Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model‏
670 ‎‡a Author's Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.‏
670 ‎‡a Author's Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.‏
670 ‎‡a Author's Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina‏
670 ‎‡a Author's Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours.‏
670 ‎‡a Author's Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas‏
670 ‎‡a Author's Implication of von Willebrand factor as a regulator of tumor cell metastasis: potential perioperative use of desmopressin and novel peptide analogs‏
670 ‎‡a Author's In vitro activity of a Solanum tuberosum extract against mammary carcinoma cells‏
670 ‎‡a Author's Intermittent dietary restriction in eSS diabetic rats. Effects on metabolic control and skin morphology.‏
670 ‎‡a Author's Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.‏
670 ‎‡a Author's Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.‏
670 ‎‡a Author's Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma‏
670 ‎‡a Author's Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells‏
670 ‎‡a Author's Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells‏
670 ‎‡a Author's Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach.‏
670 ‎‡a Author's Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: a pilot study‏
670 ‎‡a Author's Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.‏
670 ‎‡a Author's Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.‏
670 ‎‡a Author's Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells‏
670 ‎‡a Author's RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging‏
670 ‎‡a Author's Racotumomab for treating lung cancer and pediatric refractory malignancies.‏
670 ‎‡a Author's Re: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor‏
670 ‎‡a Author's Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis‏
670 ‎‡a Author's Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model‏
670 ‎‡a Author's Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.‏
670 ‎‡a Author's Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.‏
670 ‎‡a Author's Role of tumor-derived granulocyte-macrophage colony-stimulating factor in mice bearing a highly invasive and metastatic mammary carcinoma‏
670 ‎‡a Author's Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies‏
670 ‎‡a Author's Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches.‏
670 ‎‡a Author's Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.‏
670 ‎‡a Author's Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells‏
670 ‎‡a Author's States of stability/lysis in human fetal and adults red blood cells‏
670 ‎‡a Author's Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells‏
670 ‎‡a Author's Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.‏
670 ‎‡a Author's T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies.‏
670 ‎‡a Author's Telomere structure and telomerase in health and disease (review).‏
670 ‎‡a Author's The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.‏
670 ‎‡a Author's The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.‏
670 ‎‡a Author's Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells-Letter.‏
670 ‎‡a Author's Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability‏
909 ‎‡a (scopus) 7102896260‏ ‎‡9 1‏
909 ‎‡a (orcid) 000000020601613x‏ ‎‡9 1‏
919 ‎‡a varyingpatternsofexpressionofinsulinlikegrowthfactors1and2andtheirreceptorsinmurinemammaryadenocarcinomasofdifferentmetastasizingability‏ ‎‡A Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability‏ ‎‡9 1‏
919 ‎‡a functionalinteractionbetweenacylcoasynthetase45lipooxygenaseandcyclooxygenase2controlstumorgrowthanoveltherapeutictarget‏ ‎‡A The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.‏ ‎‡9 1‏
919 ‎‡a noveldesmopressinanalogueddavpinhibitsangiogenesistumourgrowthandmetastasesinvasopressintype2receptorexpressingbreastcancermodels‏ ‎‡A The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.‏ ‎‡9 1‏
919 ‎‡a urokinaseexertsantimetastaticeffectsbydissociatingclustersofcirculatingtumorcellsletter‏ ‎‡A Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells-Letter.‏ ‎‡9 1‏
919 ‎‡a detectionandcharacterizationofnglycolyatedgangliosidesinwilmstumorbyimmunohistochemistry‏ ‎‡A Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry‏ ‎‡9 1‏
919 ‎‡a desmopressininhibitslungandlymphnodemetastasisinamousemammarycarcinomamodelofsurgicalmanipulation‏ ‎‡A Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation.‏ ‎‡9 1‏
919 ‎‡a deregulationofthesignalingpathwayscontrollingurokinaseproductionitsrelationshipwiththeinvasivephenotype‏ ‎‡A Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.‏ ‎‡9 1‏
919 ‎‡a cytoreductivesurgeryandhyperthermicintraperitonealchemotherapyincolorectalcancerpotentialuseofperioperativedesmopressintoreduceallogenicbloodtransfusionrates‏ ‎‡A Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer: Potential use of Perioperative Desmopressin to Reduce Allogenic Blood Transfusion Rates‏ ‎‡9 1‏
919 ‎‡a completeantitumorprotectionbyperioperativeimmunizationwithgm3vsspvaccineinapreclinicalmousemelanomamodel‏ ‎‡A Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model‏ ‎‡9 1‏
919 ‎‡a comparabilityofantibodymediatedcellkillingactivitybetweenaproposedbiosimilarrtxm83andtheoriginatorrituximab‏ ‎‡A Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.‏ ‎‡9 1‏
919 ‎‡a cirrhosisvonwillebrandfactorvwfandthelowincidenceofmetastaticmalignancyininjuredliver‏ ‎‡A Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured Liver‏ ‎‡9 1‏
919 ‎‡a cigb300anantick2peptideinhibitsangiogenesistumorcellinvasionandmetastasisinlungcancermodels‏ ‎‡A CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models‏ ‎‡9 1‏
919 ‎‡a cigb300aproapoptoticpeptideinhibitsangiogenesisinvitroandinvivo‏ ‎‡A CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo‏ ‎‡9 1‏
919 ‎‡a cigb300anovelproapoptoticpeptidethatimpairstheck2phosphorylationandexhibitsanticancerpropertiesbothinvitroandinvivo‏ ‎‡A CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo‏ ‎‡9 1‏
919 ‎‡a telomerestructureandtelomeraseinhealthanddiseasereview‏ ‎‡A Telomere structure and telomerase in health and disease (review).‏ ‎‡9 1‏
919 ‎‡a tcellsarecrucialfortheantimetastaticeffectofantiepidermalgrowthfactorreceptorantibodies‏ ‎‡A T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies.‏ ‎‡9 1‏
919 ‎‡a systemicadministrationofapeptidethatimpairstheproteinkinaseck2phosphorylationreducessolidtumorgrowthinmice‏ ‎‡A Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.‏ ‎‡9 1‏
919 ‎‡a structureactivityrelationshipof1desamino8500argininevasopressinasanantiproliferativeagentonhumanvasopressinv2receptorexpressingcancercells‏ ‎‡A Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells‏ ‎‡9 1‏
919 ‎‡a statesofstabilitylysisinhumanfetalandadultsredbloodcells‏ ‎‡A States of stability/lysis in human fetal and adults red blood cells‏ ‎‡9 1‏
919 ‎‡a solublefactorsreleasedbythetargetorganenhancetheurokinasetypeplasminogenactivatoractivityofmetastatictumorcells‏ ‎‡A Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells‏ ‎‡9 1‏
919 ‎‡a sensitivityoftumorcellstowardscigb300anticancerpeptidereliesonitsnucleolarlocalization‏ ‎‡A Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.‏ ‎‡9 1‏
919 ‎‡a searchofvasopressinanalogswithantiproliferativeactivityonsmallcelllungcancerdrugdesignbasedon2differentapproaches‏ ‎‡A Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches.‏ ‎‡9 1‏
919 ‎‡a safetyandpreliminaryefficacydataofanovelcaseinkinase2ck2peptideinhibitoradministeredintralesionallyat4doselevelsinpatientswithcervicalmalignancies‏ ‎‡A Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies‏ ‎‡9 1‏
919 ‎‡a roleoftumorderivedgranulocytemacrophagecolonystimulatingfactorinmicebearingahighlyinvasiveandmetastaticmammarycarcinoma‏ ‎‡A Role of tumor-derived granulocyte-macrophage colony-stimulating factor in mice bearing a highly invasive and metastatic mammary carcinoma‏ ‎‡9 1‏
919 ‎‡a roleofcellsurfacegm3gangliosideandsialicacidintheantitumoractivityofagm3basedvaccineinthemurineb16melanomamodel‏ ‎‡A Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.‏ ‎‡9 1‏
919 ‎‡a relevanceofsmallgtpaserac1pathwayindrugandradioresistancemechanismsopportunitiesincancertherapeutics‏ ‎‡A Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.‏ ‎‡9 1‏
919 ‎‡a reductionoftumorangiogenesisinducedbydesmopressininabreastcancermodel‏ ‎‡A Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model‏ ‎‡9 1‏
919 ‎‡a reductionofmousemammarytumorformationandmetastasisbylovastatinaninhibitorofthemevalonatepathwayofcholesterolsynthesis‏ ‎‡A Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis‏ ‎‡9 1‏
919 ‎‡a reeffectofadam28oncarcinomacellmetastasisbycleavageofvonwillebrandfactor‏ ‎‡A Re: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor‏ ‎‡9 1‏
919 ‎‡a racotumomabfortreatinglungcancerandpediatricrefractorymalignancies‏ ‎‡A Racotumomab for treating lung cancer and pediatric refractory malignancies.‏ ‎‡9 1‏
919 ‎‡a rac3morethananuclearreceptorcoactivatorakeyinhibitorofsenescencethatisdownregulatedinaging‏ ‎‡A RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging‏ ‎‡9 1‏
919 ‎‡a proapoptoticandantiinvasiveactivityofrac1smallmoleculeinhibitorsonmalignantgliomacells‏ ‎‡A Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells‏ ‎‡9 1‏
919 ‎‡a preclinicaldevelopmentofnovelrac1gefsignalinginhibitorsusingarationaldesignapproachinhighlyaggressivebreastcancercelllines‏ ‎‡A Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.‏ ‎‡9 1‏
919 ‎‡a pharmacologicalinhibitionofrac1pak1axisrestorestamoxifensensitivityinhumanresistantbreastcancercells‏ ‎‡A Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.‏ ‎‡9 1‏
919 ‎‡a perioperativedesmopressinprolongssurvivalinsurgicallytreatedbitcheswithmammaryglandtumoursapilotstudy‏ ‎‡A Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: a pilot study‏ ‎‡9 1‏
919 ‎‡a perioperativebiologyinprimarybreastcancerselectivetargetingofvasopressintype2receptorusingdesmopressinasanoveltherapeuticapproach‏ ‎‡A Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach.‏ ‎‡9 1‏
919 ‎‡a peptideagonistsofvasopressinv2receptorreduceexpressionofneuroendocrinemarkersandtumorgrowthinhumanlungandprostatetumorcells‏ ‎‡A Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells‏ ‎‡9 1‏
919 ‎‡a overproductionofurokinasetypeplasminogenactivatorisregulatedbyphospholipase500andproteinkinase100dependentpathwaysinmurinemammaryadenocarcinomacells‏ ‎‡A Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells‏ ‎‡9 1‏
919 ‎‡a minimaldisseminateddiseaseevaluationandoutcomeintrilateralretinoblastoma‏ ‎‡A Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma‏ ‎‡9 1‏
919 ‎‡a cancerantigenprioritizationaroadmaptoworkindefiningvaccinesagainstspecifictargetsapointofview‏ ‎‡A Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.‏ ‎‡9 1‏
919 ‎‡a mechanismsofcellularuptakeintracellulartransportationanddegradationofcigb300atatconjugatedpeptideintumorcelllines‏ ‎‡A Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.‏ ‎‡9 1‏
919 ‎‡a antitumoreffectofanovelproapoptoticpeptidethatimpairsthephosphorylationbytheproteinkinase2caseinkinase2‏ ‎‡A Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).‏ ‎‡9 1‏
919 ‎‡a lovastatinalterscytoskeletonorganizationandinhibitsexperimentalmetastasisofmammarycarcinomacells‏ ‎‡A Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.‏ ‎‡9 1‏
919 ‎‡a intermittentdietaryrestrictioninessdiabeticratseffectsonmetaboliccontrolandskinmorphology‏ ‎‡A Intermittent dietary restriction in eSS diabetic rats. Effects on metabolic control and skin morphology.‏ ‎‡9 1‏
919 ‎‡a invitroactivityofasolanumtuberosumextractagainstmammarycarcinomacells‏ ‎‡A In vitro activity of a Solanum tuberosum extract against mammary carcinoma cells‏ ‎‡9 1‏
919 ‎‡a implicationofvonwillebrandfactorasaregulatoroftumorcellmetastasispotentialperioperativeuseofdesmopressinandnovelpeptideanalogs‏ ‎‡A Implication of von Willebrand factor as a regulator of tumor cell metastasis: potential perioperative use of desmopressin and novel peptide analogs‏ ‎‡9 1‏
919 ‎‡a impairmentoffibrinolysisduringthegrowthof2murinemammaryadenocarcinomas‏ ‎‡A Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas‏ ‎‡9 1‏
919 ‎‡a immunoreactivityofthe14f7mabraisedagainstnglycolylgm3gangliosideinretinoblastomatumours‏ ‎‡A Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours.‏ ‎‡9 1‏
919 ‎‡a antimetastaticeffectofdesmopressininamousemammarytumormodel‏ ‎‡A Antimetastatic effect of desmopressin in a mouse mammary tumor model‏ ‎‡9 1‏
919 ‎‡a anticancerpeptidecigb300bindstonucleophosminb23impairsitsck2mediatedphosphorylationandleadstoapoptosisthroughitsnucleolardisassemblyactivity‏ ‎‡A Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.‏ ‎‡9 1‏
919 ‎‡a antibodydependentcellmediatedcytotoxicityinducedbyactiveimmunotherapybasedonracotumomabinnonsmallcelllungcancerpatients‏ ‎‡A Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients‏ ‎‡9 1‏
919 ‎‡a antigangliosideantibodiesinducedinchickensbyanalumadsorbedantiidiotypeantibodytargetingneugcgm3‏ ‎‡A Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.‏ ‎‡9 1‏
919 ‎‡a additionofvasopressinsyntheticanalogueddavptostandardchemotherapyenhancestumourgrowthinhibitionandimpairsmetastaticspreadinaggressivebreasttumourmodels‏ ‎‡A Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.‏ ‎‡9 1‏
919 ‎‡a additionofvasopressinsyntheticanalogue5‏ ‎‡A Addition of vasopressin synthetic analogue [V‏ ‎‡9 1‏
919 ‎‡a highlightsfromthe1latinamericanmeetingonmetronomicchemotherapyanddrugrepositioninginoncology2728may2016rosarioargentina‏ ‎‡A Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina‏ ‎‡9 1‏
919 ‎‡a gangliosidebasedvaccinesandantiidiotypeantibodiesforactiveimmunotherapyagainstcancer‏ ‎‡A Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.‏ ‎‡9 1‏
919 ‎‡a exogenousincorporationofneugcrichmucinaugmentsnglycolylsialicacidcontentandpromotesmalignantphenotypeinmousetumorcelllines‏ ‎‡A Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.‏ ‎‡9 1‏
919 ‎‡a purifiedgm3gangliosideconjugatedvaccineinducesspecificadjuvantdependentandnontransientantitumouractivityagainstb16mousemelanomainvitroandinvivo‏ ‎‡A A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.‏ ‎‡9 1‏
919 ‎‡a phase2doseescalationtrialofperioperativedesmopressin1desamino8500argininevasopressininbreastcancerpatients‏ ‎‡A A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.‏ ‎‡9 1‏
919 ‎‡a phase1studyoftheantiidiotypevaccineracotumomabinneuroblastomaandotherpediatricrefractorymalignancies‏ ‎‡A A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies‏ ‎‡9 1‏
919 ‎‡a effectsofsyntheticurokinaseinhibitorsonlocalinvasionandmetastasisinamurinemammarytumormodel‏ ‎‡A Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model‏ ‎‡9 1‏
919 ‎‡a effectofatorvastatininacaseoffelinemulticentriclymphomacasereport‏ ‎‡A Effect of atorvastatin in a case of feline multicentric lymphoma - Case report‏ ‎‡9 1‏
919 ‎‡a directvalidationofngcgm3gangliosideasanewtargetforcancerimmunotherapy‏ ‎‡A Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.‏ ‎‡9 1‏
919 ‎‡a detectionofminimallydisseminateddiseaseinthecerebrospinalfluidofchildrenwithhighriskretinoblastomabyreversetranscriptasepolymerasechainreactionforgd2synthasemrna‏ ‎‡A Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA.‏ ‎‡9 1‏
919 ‎‡a 7a7mabanewtoolforthepreclinicalevaluationofegfrbasedtherapies‏ ‎‡A 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 NII|DA18149900‏
996 ‎‡2 BNF|14000657‏
996 ‎‡2 DNB|1122060122‏
996 ‎‡2 J9U|987007360687405171‏
996 ‎‡2 LC|n 93100893‏
996 ‎‡2 SUDOC|083922091‏
996 ‎‡2 LC|n 2014066623‏
996 ‎‡2 SUDOC|280722893‏
996 ‎‡2 LC|no2016028511‏
996 ‎‡2 BNE|XX6350290‏
996 ‎‡2 BNE|XX4706433‏
996 ‎‡2 BNE|XX5477287‏
996 ‎‡2 LC|no2017091002‏
996 ‎‡2 CAOONL|ncf11533777‏
996 ‎‡2 ISNI|000000009693123X‏
996 ‎‡2 BNE|XX5504370‏
996 ‎‡2 BNE|XX1699816‏
996 ‎‡2 LC|no2012085275‏
996 ‎‡2 ISNI|0000000118176635‏
996 ‎‡2 BNF|17890397‏
996 ‎‡2 DNB|1056354542‏
996 ‎‡2 BIBSYS|1479731351927‏
996 ‎‡2 LC|no2017145753‏
996 ‎‡2 BNE|XX926640‏
996 ‎‡2 ISNI|0000000495893402‏
996 ‎‡2 SUDOC|254039405‏
996 ‎‡2 SUDOC|252775457‏
996 ‎‡2 CAOONL|ncf10144314‏
996 ‎‡2 ISNI|0000000120063955‏
996 ‎‡2 ISNI|0000000474739983‏
996 ‎‡2 LC|no2019046657‏
996 ‎‡2 BNE|XX1417420‏
996 ‎‡2 RERO|A026565688‏
996 ‎‡2 SZ|1089599137‏
996 ‎‡2 BNE|XX5612906‏
996 ‎‡2 BNE|XX4771416‏
996 ‎‡2 CAOONL|ncf11635071‏
996 ‎‡2 RERO|A002921148‏
996 ‎‡2 J9U|987007357711605171‏
996 ‎‡2 DNB|1070807354‏
996 ‎‡2 ISNI|0000000078971377‏
996 ‎‡2 DNB|1080011501‏
996 ‎‡2 LC|n 2022001550‏
996 ‎‡2 BNE|XX5141991‏
996 ‎‡2 BNE|XX6218018‏
996 ‎‡2 BNE|XX1181303‏
996 ‎‡2 NLA|000035847556‏
996 ‎‡2 LC|n 85319075‏
996 ‎‡2 DNB|1089599137‏
996 ‎‡2 BNE|XX1026389‏
996 ‎‡2 BNE|XX4732274‏
996 ‎‡2 ISNI|000000044004477X‏
996 ‎‡2 BNE|XX5594262‏
996 ‎‡2 LC|nr2005006324‏
996 ‎‡2 SUDOC|270854754‏
996 ‎‡2 BNC|981058511502806706‏
996 ‎‡2 BLBNB|001422096‏
996 ‎‡2 BNE|XX1660145‏
996 ‎‡2 DNB|1140853759‏
996 ‎‡2 LC|n 86007431‏
996 ‎‡2 DNB|1257805665‏
996 ‎‡2 ISNI|0000000080182617‏
996 ‎‡2 SUDOC|250507994‏
996 ‎‡2 RERO|A020309822‏
996 ‎‡2 ISNI|0000000122684333‏
996 ‎‡2 DNB|1194423116‏
996 ‎‡2 LC|n 2017073742‏
996 ‎‡2 ISNI|0000000471437437‏
996 ‎‡2 RERO|A011685436‏
996 ‎‡2 DNB|1346056145‏
996 ‎‡2 LC|n 2023047117‏
996 ‎‡2 BLBNB|000675658‏
996 ‎‡2 DNB|1305862279‏
996 ‎‡2 NUKAT|nx2023629087‏
996 ‎‡2 ISNI|000000050414114X‏
996 ‎‡2 BNE|XX5526621‏
996 ‎‡2 BNE|XX4778101‏
996 ‎‡2 SUDOC|267128592‏
996 ‎‡2 LC|no2012050954‏
996 ‎‡2 SUDOC|255545932‏
996 ‎‡2 BNF|16190885‏
996 ‎‡2 DNB|1217354077‏
996 ‎‡2 SUDOC|178221015‏
996 ‎‡2 RERO|A026152665‏
996 ‎‡2 BNE|XX1739598‏
996 ‎‡2 NUKAT|n 2022036133‏
996 ‎‡2 PLWABN|9810689795205606‏
996 ‎‡2 BNF|17769498‏
996 ‎‡2 LC|n 2010059182‏
996 ‎‡2 CAOONL|ncf11025279‏
996 ‎‡2 BNE|XX1627083‏
996 ‎‡2 BNE|XX5401868‏
996 ‎‡2 LC|no2005115614‏
996 ‎‡2 LC|n 2019010469‏
996 ‎‡2 ISNI|0000000378695458‏
996 ‎‡2 ISNI|0000000077329083‏
996 ‎‡2 DNB|1147098387‏
996 ‎‡2 SELIBR|336550‏
996 ‎‡2 BNE|XX1785258‏
996 ‎‡2 DNB|1096258390‏
996 ‎‡2 SUDOC|224717014‏
996 ‎‡2 SUDOC|249390043‏
996 ‎‡2 BNE|XX973028‏
996 ‎‡2 J9U|987007325340305171‏
996 ‎‡2 DNB|1056771062‏
996 ‎‡2 LC|n 2021061935‏
996 ‎‡2 RERO|A025331035‏
996 ‎‡2 ISNI|0000000425608725‏
996 ‎‡2 BNE|XX6105067‏
996 ‎‡2 BNC|981061129449506706‏
996 ‎‡2 NTA|320646866‏
996 ‎‡2 BNE|XX4729143‏
996 ‎‡2 BNE|XX1224311‏
996 ‎‡2 SUDOC|279308574‏
996 ‎‡2 BNC|981058611769306706‏
996 ‎‡2 SUDOC|27278057X‏
996 ‎‡2 CAOONL|ncf13736884‏
996 ‎‡2 PLWABN|9812735111105606‏
996 ‎‡2 NTA|13380254X‏
996 ‎‡2 BNE|XX6490289‏
996 ‎‡2 LC|no2008051908‏
996 ‎‡2 BIBSYS|97040990‏
996 ‎‡2 NUKAT|n 2014167985‏
996 ‎‡2 SZ|1122060122‏
996 ‎‡2 BNE|XX1651836‏
996 ‎‡2 BNE|XX5016725‏
996 ‎‡2 ISNI|0000000093773061‏
996 ‎‡2 SUDOC|082126771‏
996 ‎‡2 LIH|LNB:CKRX;=BU‏
996 ‎‡2 BNE|XX1005990‏
996 ‎‡2 BNE|XX882714‏
996 ‎‡2 ISNI|0000000060422660‏
996 ‎‡2 SUDOC|273684744‏
996 ‎‡2 BNE|XX4660825‏
996 ‎‡2 CAOONL|ncf11862291‏
996 ‎‡2 BNC|981059746259706706‏
996 ‎‡2 BNE|XX4929338‏
996 ‎‡2 BNE|XX5130011‏
996 ‎‡2 ISNI|0000000024208747‏
996 ‎‡2 BNE|XX1378716‏
996 ‎‡2 BNF|17789429‏
996 ‎‡2 ISNI|0000000498840410‏
996 ‎‡2 ISNI|0000000059213968‏
996 ‎‡2 BNC|981058516792606706‏
996 ‎‡2 RERO|A011373619‏
996 ‎‡2 ISNI|0000000094836335‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏